Format

Send to

Choose Destination
Cancer Invest. 2019;37(3):144-155. doi: 10.1080/07357907.2019.1582060. Epub 2019 Mar 25.

Targeting Glioma Stem Cells by Functional Inhibition of Dynamin 2: A Novel Treatment Strategy for Glioblastoma.

Author information

1
a Department of Surgery , The University of Melbourne, The Royal Melbourne Hospital , Parkville , Australia.
2
b Department of Neurosurgery , The Royal Melbourne Hospital , Parkville , Australia.
3
c Department of Medicine , The University of Melbourne, The Royal Melbourne Hospital , Parkville , Australia.
4
d Melbourne School of Engineering, School of Chemical and Biomedical Engineering , The University of Melbourne , Parkville , Australia.
5
e Department of Chemistry, School of Environmental and Life Sciences , The University of Newcastle , Callaghan , Australia.
6
f Department of Neuroscience , Central Clinical School, Monash University , Melbourne , Australia.
7
g Department of Neurology , The Alfred Hospital , Melbourne , Australia.
8
h Children's Medical Research Institute, The University of Sydney , Westmead , Australia.

Abstract

Glioma stem cells (GSCs) play major roles in drug resistance, tumour maintenance and recurrence of glioblastoma. We investigated inhibition of the GTPase dynamin 2 as a therapy for glioblastoma. Glioma cell lines and patient-derived GSCs were treated with dynamin inhibitors, Dynole 34-2 and CyDyn 4-36. We studied about cell viability, and GSC neurosphere formation in vitro and orthotopic tumour growth in vivo. Dynamin inhibition reduced glioblastoma cell line viability and suppressed neurosphere formation and migration of GSCs. Tumour growth was reduced by CyDyn 4-36 treatment. Dynamin 2 inhibition therefore represents a novel approach for stem cell-directed Glioblastoma therapy.

KEYWORDS:

Cancer biology; Cancer stem cells; Dynamin; Glioblastoma; Invasion

PMID:
30907150
DOI:
10.1080/07357907.2019.1582060
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center